Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Anacor, a privately held, clinical-stage pharmaceutical company, is developing novel product candidates for inflammatory and infectious diseases based on its proprietary, small-molecule, boron-based chemistry. Initially, Anacor is focusing development efforts on dermatological disorders with AN2690 in Phase 2 trials for onychomycosis, a fungal infection of nails and nailbeds. A second product candidate, AN0128, is in Phase 2 clinical trials for atopic dermatitis. ( www.anacor.com )
Anacor Pharmaceuticals
1060 East Meadow Circle
Palo Alto, California 94303-4230
USA
Tel: (650) 739-0700
Fax: (650) 739-0139